WELL Health Technologies Corp (WELL – Research Report), the Healthcare company, was revisited by a Wall Street analyst today. The Healthcare company, WELL Health Technologies Corp (TSX: WELL) has just received a rating update from a Wall Street analyst.
According to TipRanks.com, Keywood is a 1-star analyst with an average return of -0.7% and a 38.4% success rate. Keywood covers the Healthcare sector, focusing on stocks such as Andlauer Healthcare Group, Cipher Pharmaceuticals, and Knight Therapeutics.
Currently, the analyst consensus on WELL Health Technologies Corp is a Strong Buy with an average price target of C$8.36, representing an 117.1% upside. In a report issued on November 9, Scotiabank also maintained a Buy rating on the stock with a C$6.50 price target.
WELL Health Technologies Corp’s market cap is currently C$926.6M and has a P/E ratio of -131.34.
WELL Health Technologies Corp is the owner and operator of a portfolio of Primary Hclinics delivering healthcare-related services It operates through below segments: Clinical services, Digital services, and others. It also engages in the Electronic Medical Records business that supports the digitization of clinics. Its objective is to empower doctors to provide the best and most advanced care possible leveraging the latest trends in digital health.
The company’s shares closed last Tuesday at C$3.73.
Read More on TSE:WELL:
- WELL Health Reports Record Results for Q3-2023, Raises Guidance for Balance of 2023 and Provides Guidance of Over $900 Million in Revenue for 2024
- WELL Upcoming Earnings Report: What to Expect?
- WELL Health’s Cycura Announces Two Tuck-In Acquisitions to Enhance Patient Data Protection and Appoints New Management
- WELL Health Completes Clinic Acquisition and Investment Transactions with HEALWELL AI Inc. (formerly MCI Onehealth), and Forms Strategic Alliance Focused on Developing AI Enabled Disease Detection and Preventative Care Tools for Care Providers
